A multicenter phase IV clinical trial to examine the change of low-grade side effects after switch to Nilotinib from other tyrosine kinase inhibitors.

Trial Profile

A multicenter phase IV clinical trial to examine the change of low-grade side effects after switch to Nilotinib from other tyrosine kinase inhibitors.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 03 Jun 2014

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 19 May 2014 Status changed from suspended to discontinued as reported by University Hospital Medical Information Network - Japan..
    • 27 Jan 2014 Status changed from recruiting to suspended as per University Hospital Medical Information Network - Japan record.
    • 04 Oct 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top